

Applied Therapeutics

Corporate Presentation

October 2021



Disclaimer

This presentation is made by Applied Therapeutics, Inc. (the “Company”). Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy the Company’s securities, nor shall there be any sale of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Various statements in this presentation concerning the Company’s future expectations, plans and prospects, including without limitation, the Company’s current expectations regarding its strategy, its product candidate selection and development timing, its management team capabilities, and the ability of the Company’s product candidates to have a clinically meaningful effect on the target patient populations, constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Such risks include, but are not limited to: the impact of general economic conditions, general conditions in the biopharmaceutical industries, changes in the global and regional regulatory environments in the jurisdictions in which the Company does or plans to do business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company’s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our product candidates; final and quality controlled verification of data and the related analyses; the expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration and European Medicines Agency; the possibility of having to conduct additional clinical trials and our reliance on third parties such as our licensors and collaboration partners regarding our suite of technologies and product candidates. Further, even if regulatory approval is obtained, biopharmaceutical products are generally subject to stringent on-going governmental regulation, challenges in gaining market acceptance and competition.

These risks and uncertainties are described more fully under the caption “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Other risks and uncertainties of which the Company is not currently aware may also affect Company’s forward-looking statements. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

Applying Science to Transform Lives

Our mission is to create transformative, life-changing treatments for patients who desperately need them

SCIENCE



Targeting pathways with known roles in pathogenesis

Novel compounds with improved potency/selectivity

DEVELOPMENT



Clinical efficacy confirmed via biomarkers

Pursuing expedited regulatory pathways








MARKET



Fatal or debilitating diseases with no approved therapies


Limited / no competition

Innovative Pipeline with Near-Term Milestones

Compound	Preclinical	Phase 1	Phase 2	Phase 3	Dosing	Target Tissue	Milestones	WW Rights
ALDOSE REDUCTASE FRANCHISE								
AT-007	Galactosemia – Pivotal Phase 2 Study				QD Oral	CNS	Adult study completed; pediatric study ongoing NDA expected Q4 2021	
AT-007	SORD Deficiency				Oral	CNS	Pilot study completed; Registrational study Q4 2021	
AT-007	PMM2-CDG				Oral	CNS	Phase 2 ready- clinical study start 2021; Expanded Access open	
AT-001	Diabetic Cardiomyopathy – Pivotal Phase 3 Study				BID Oral	Systemic	Ph 3 trial initiated in Q3 2019; data 1H '23	
AT-001	Diabetic Peripheral Neuropathy				Oral	Peripheral Nerve	Sub-study embedded in DbCM Ph 3 trial	
AT-003	Diabetic Retinopathy				Oral	Retina	Ph 1 expected 2021	
PI3 KINASE FRANCHISE								
AT-104	PTCL, CTCL, TALL [†]				SC / Oral	Selective δ/γ inhibitor	Proof of concept preclinical 2021	

[†]Peripheral T-cell lymphoma, cutaneous T-cell lymphoma and T-cell acute lymphoblastic leukemia

Aldose Reductase Inhibitor Overview



Aldose Reductase is an enzyme implicated in multiple metabolic diseases

First and rate limiting enzyme in the polyol pathway – an alternative metabolic pathway activated under stress

Converts sugar to reduced sugar alcohols, which are toxic

Leads to cell death through osmotic dysregulation, reactive oxygen species formation, and energy deficiencies

Prior attempts to inhibit Aldose Reductase were hindered by lack of selectivity and off-target tox issues

AT-007

GALACTOSEMIA

- Orphan Drug Designation
- Pediatric Rare Disease Designation (PRV)
- Fast-Track Designation

Positive adult biomarker data; LTE ongoing

Pediatric trial ongoing

NDA expected Q4 2021



Galactosemia: a Rare Metabolic Disease With No Approved Therapies

Galactosemia is a **rare, slowly progressing metabolic disease** caused by a **genetic inability to break down the sugar galactose**. Galactose is found in foods, but the human body also naturally produces galactose on its own

~3,000 patients in the US with Galactosemia; ~80 new births per year; Mandatory newborn screening in US and most EU countries

Aldose Reductase (AR) enzyme converts galactose into **galactitol, an aberrant toxic metabolite that builds up in tissues and organs** and causes long-term disease complications


AT-007, a novel CNS penetrant Aldose Reductase inhibitor, **prevents galactitol formation and accumulation** in adult and pediatric Galactosemia patients; pediatric long-term outcomes study ongoing

Low burden of development due to biomarker-based program under new FDA guidance for low prevalence diseases

Small commercial footprint required to launch quickly and effectively; strong community engagement with disease state awareness efforts reflects underlying demand

Patent exclusivity through 2037; Orphan and Pediatric Rare Disease designations granted

Galactosemia Development History

- 
- 1940-1956 LeLoir Pathway discovered; deficiency in galactose metabolism identified as cause of disease by Kalckar et al
- 1990s 2 different disease hypotheses emerge: 1) Gal-1p hypothesized to be responsible for disease pathogenesis due to absence of GALK patients with defined phenotype; 2) Galactitol hypothesized to be responsible for pathogenesis due to known toxicity of sugar alcohols and autopsies demonstrating high galactitol in the brain of Galactosemia infants
- 1995 GALT null mouse genetically engineered. Displays high galactose and Gal-1p, but no galactitol (mice don't express AR) resulting in no disease phenotype; suggests galactitol, not Gal-1p, responsible for disease.
- 1990's-2005 Newborn screening implemented - mandatory in the US in 2005; Broad acceptance at the time that newborn screening + diet would prevent disease; Unfortunately this did prevent newborn deaths but not long-term complications.
- 2004 Endogenous galactose production discovered. As the body produces galactose at 10X levels ingested on a Galactosemia diet, this explained long-term complications and raised recognition that diet is not enough.
- 2011 First large study of GALK-deficient patients in Germany, demonstrating disease phenotype similar to GALT-deficient patients. GALK patients have high galactose and galactitol, but do not produce Gal-1p.
- 2018 GALT null rat genetically engineered. Displays high galactose, Gal-1p and galactitol and develops CNS abnormalities and cataracts; again, suggests galactitol (not Gal-1p) is responsible for disease phenotype.
- 2019 GALT null rat treated with Aldoses Reductase Inhibitor (AT-007). Galactitol reduction normalized CNS phenotype and prevented cataracts. Galactitol confirmed as pathogenic cause of Galactosemia.

Galactosemia: Disease Progression is Slow But Debilitating



Newborn

- Liver failure
- Kidney problems
- Sepsis
- Brain edema
- Pseudotumor cerebri
- Feeding difficulties
- Growth problems
- Cataracts



Infants/Toddlers

- Speech/language delays
- Coordination problems (fine and gross motor skills)
- Developmental delays
- Attention issues
- Growth problems
- Cataracts



Young Children

- Learning delays
- Issues with fine and gross motor skills (e.g., handwriting)
- Growth problems
- Speech/language problems
- Behavioral and emotional issues
- Tremor



Teen


- Puberty and fertility problems (females)
- Growth delays
- Anxiety
- Social problems
- Learning difficulties
- Tremor



Adult

- Tremor
- Seizures
- Anxiety
- Depression
- Attention Deficit Hyperactivity Disorder (ADHD)
- Cataracts

Cross Sectional Analysis of Outcomes on 19 Children Age 3-15 Demonstrates Significant Progressive Worsening of Disease Over Time




Abstract eP011: Progressive Worsening of Central Nervous System Phenotype in Children with Classic Galactosemia: a Cross-Sectional Analysis;; ACMG 2021 conference


Galactosemia: Deficiency in GALT or GALK Leads to Inability to Metabolize Galactose; Aldose Reductase Converts Excess Galactose to Toxic Galactitol

- Galactitol is an aberrant metabolite
- Healthy people (without Galactosemia) do not have measurable levels of galactitol in blood or tissues
- Mean plasma galactitol level for adults with Galactosemia on a restricted diet in ACTION-Galactosemia study was ~2,500ng/mL
- Mean plasma galactitol level for children with Galactosemia on a restricted diet in ACTION-Galactosemia-Kids was ~2,000ng/mL


NORMAL METABOLISM




GALACTOSEMIA



AT-007 Blocks Aldose Reductase Conversion of Galactose to Galactitol; Galactose is then shunted through a nontoxic pathway for metabolism and excretion




In a Rat Model of Galactosemia, AT-007 Significantly Reduced Toxic Galactitol Levels in All Target Tissues Without Increasing Galactose or Gal-1P




AT-007 treatment from neonatal Day 1 to Day 10 significantly reduced galactitol in liver, brain and plasma
AT-007 treatment did not increase galactose or Gal-1P levels; similar results seen at Day 22 and age 5 months

AT-007 Treatment Prevented the CNS Phenotype of Disease, Including Learning, Cognition and Motor Deficiencies, and Prevented Cataracts

AT-007 treatment normalized CNS outcomes on both water maze and rotarod



AT-007 treatment prevented galactitol accumulation in tissues, resulting in absence of cataracts



In contrast, GALT null mouse did not display a phenotype – GALT null mice display high galactose + Gal1-p but not galactitol (mice don't express AR)

Rats were on a lactose-restricted diet similar to humans; rat breast milk contains very low lactose levels; supplemented with soy formula; rat chow has low galactose levels similar to allowed foods such as legumes

Galactosemia Phase 1/2 Registrational Study (ACTION-Galactosemia)

Multi-Center Placebo-Controlled Study in Healthy Volunteers & Adult Galactosemia Patients

Healthy Volunteers

Single Ascending Dose
(n=40)

Multiple Ascending Dose
(n=40, 7 days)

Endpoints:

- Safety
- Pharmacokinetics
- CNS Penetrance (via CSF sample)

Endpoints:

- Safety
- Pharmacokinetics/
Pharmacodynamics
- Efficacy Biomarker –
Galactitol

Adult Galactosemia Patients**

**5 mg/kg
single dose**

5 mg/kg 27 Days Daily Dosing
(n=4)

**20 mg/kg
Single dose**

20mg/kg 27 Days Daily Dosing
(n=4)

**40 mg/kg*
Single dose**

40mg/kg 27 Days Daily Dosing
(n=4)

**Placebo
Single dose**

Placebo 27 Days Daily Dosing
(n=6)

**3 Month
Extension**

*Based on initial topline data from Jan 2020, the study was expanded to include a 40mg/kg dose in healthy volunteers and then Galactosemia patients. This cohort also included 2 additional placebo patients

**Due to the small size of the population and burden of study participation (travel, missed work for caregivers etc), the protocol proactively allowed for patients to participate in more than 1 cohort. If participating in a second cohort, the patient had to remain blinded, washout for ≥ 1 month, and a new baseline was taken. (Crossover design is in line with FDA guidance)
Patients were on lactose-restricted diet prior to enrollment and throughout study

Healthy Volunteer Data Demonstrated Safety, CNS Penetrance, PK Supportive of QD Dosing

Safety


~80 healthy volunteers treated

AT-007 was safe and well tolerated at all doses




Brain Penetrance

Drug crosses into brain when dosed orally (CNS penetrant)



Pharmacokinetics


Dose-dependent increase in exposure; supportive of once daily oral dosing



AT-007 Decreased Galactitol Levels in All Treated Patients

Decrease was dose-dependent, rapid and sustained; statistically significant at 20 & 40mg/kg


Individual Maximum Reduction in Galactitol Percent Change From Baseline



Further Characterization of AT-007 in adult Galactosemia patients is ongoing in a long-term safety study


AT-007 Galactitol Reduction is Rapid and Sustained, Beginning on 1st Day of Treatment and Sustained Over 1 Month of Treatment

Galactitol reduction is sustained over the 24hr dosing period at steady state (Day 12 and Day 32), supporting once daily oral dosing



Data for each cohort is shown as mean +SEM; Baseline mean galactitol was not statistically different between cohorts

AT-007 Significantly Decreased Galactitol Levels; Safe and Well Tolerated



$P < 0.01$ for 20mg/kg vs. placebo and 40mg/kg vs. placebo

Placebo group updated to include 2 additional patients who participated in 40mg/kg cohort

Maximal reduction on Day 32

Safety


- Favorable safety and tolerability in core study and 3-month extension

Pharmacokinetics/ Pharmacodynamics

- PK supports once-daily dosing
- Rapid and sustained reduction in plasma galactitol
- Galactitol reduction in the brain demonstrated by MR Spectroscopy

All biomarker assays were developed, validated, and performed by Icon Labs Whitesboro, NY (independent 3rd party lab)

ACTION-Galactosemia Kids Pediatric Registrational Clinical Study (Children 2-17 years old)



- Dose range finding PK/PD study to determine optimal dose in children and biomarker-based assessment of galactitol reduction for NDA submission under Accelerated Approval
- Long-term clinical outcomes to assess impact on how patients feel and function and to provide long-term safety data

Outcomes Assessed by Composite Endpoint Consisting of 4 Quadrants: Speech, Cognition, Behavior, Motor Skills



Speech

- Expressive Language
- Receptive Language

OWLS-2 (Oral & Written Language Skills 2);
Picture Vocabulary Test; Oral Reading Recognition Test



Cognition & Learning

- Cognitive and Intellectual Development
- Attention
- Executive Function
- Memory (episodic and working memory)
- Processing speed

NIH Toolbox Cognition Battery:
Flanker Inhibitory Control & Attention Test; Dimensional Change Card Sort; Picture Sequence Memory; List Sorting; Pattern Comparison Processing Speed



Behavioral / Psychosocial

- Atypical Behavior
- Mental Health (Anxiety/Depression)
- Adaptive/Behavior Social Skills
- Communication

Behavior Assessment System for Children (BASC); Vineland Adaptive Behavior Scales



Motor Skills

- Dexterity
- Balance
- Gait Coordination
- Tremor

9-Hole Pegboard; Standing Balance; Scale for Assessment & Rating of Ataxia (SARA); Spiral Drawing Test

Baseline Characteristics of Children Enrolled in ACTION-Galactosemia Kids

AGE	GENDER	RACE	Allele 1	Allele 2
16	Female	White	Q188R	other
16	Female	White	Q188R	other
13	Male	White	Q188R	Y209C
13	Male	White	K285N	K285N
14	Female	White	Q188R	other
15	Male	White	in process	in process
13	Female	White	in process	in process
16	Female	White	in process	in process
13	Male	White	in process	in process
13	Female	White	in process	in process
16	Male	White	Q188R	Q188R
16	Female	White	Q188R	other
10	Female	Hispanic	Q188R	Q188R
10	Male	White	Q188R	Q188R
10	Male	White	Q188R	N314D
12	Male	White	Q188R	Q188R
10	Female	White	Q188R	Y209C
7	Male	White	Q188R	Q188R
2	Male	White	Q188R	other
13	Female	White	Q188R	Q188R
7	Male	White	Q188R	M142K
5	Male	White	Q188R	K285N
6	Female	White	Q188R	K285N
4	Female	White	in process	in process


AGE	GENDER	RACE	Allele 1	Allele 2
12	Female	White	Q188R	other
11	Female	White	Q188R	other
9	Female	White	Q188R	L195P
9	Male	White	Q188R	other
12	Male	White	K285N	other
10	Male	White	K285N	other
9	Male	White	K285N	other
7	Male	White	other	other
12	Female	White	S135L	other
8	Female	White	Q188R	Deletion 5kb
8	Female	White	Q188R	Q188R
7	Male	White	in process	in process
4	Female	White	Q188R	other
4	Female	White	Q188R	Q188R
3	Female	White	Q188R	Q188R
5	Male	White	Q188R	K285N
6	Male	White	N314D	Y209C
5	Female	White	K285N	other
3	Male	White	K285N	other
4	Male	White	Q188R	L195P
3	Female	White	Q188R	Q188R
6	Female	White	Q188R	Q334K
2	Male	White	in process	in process

Summary Baseline Characteristics

Mean Age	Gender	Race	Genetics*
9	24 Female	46 White	homozygous Q188R (10); homozygous K285N (1)
	23 Male	1 Hispanic	compound heterozygous (28); in process (8)

Plasma Galactitol Level at Baseline Correlates with Severity of Disease

Analysis of the 47 children in the ACTION-Galactosemia Kids study demonstrated a correlation between baseline galactitol level and baseline clinical functional outcomes



- Broad range of GALT mutations captured in the large number of children studied in ACTION-Galactosemia Kids permitted an analysis of a wide range of baseline galactitol with severity of disease.
- This data is the first demonstration of correlation of a biochemical biomarker with severity of disease in Galactosemia patients. Full data will be presented at a future medical conference.


AT-007 Demonstrates Substantial and Statistically Significant Reduction in Plasma Galactitol in Children in ACTION-Galactosemia Kids

Weight Group	AT-007 Dose	% Reduction From Baseline
>40kg	15mg/kg	38.29%
20-40kg	20mg/kg	41.43%
<20kg	30mg/kg	39.83%
All groups combined	15-30mg/kg	40.19% (p<0.001)

Safe and well-tolerated; no compensatory increase in galactose or Gal-1p

Commercial Strategy: Potential U.S. Launch Will Focus on Medical Geneticists

Preliminary U.S. Sales Territory Heat Map




Commercialization Plan Linked to Opportunity:

- Small specialty sales force focused on high-volume providers @ COEs
- Efficient digital marketing to educate lower volume specialists and facilitate non-personal promotion
- Robust patient services program to support patient on-boarding, compliance and persistence
- Pricing expected to be in-line with similar rare disease therapies for conditions of high unmet need
- U.S. Galactosemia patients have largely Commercial or Government coverage

KOL Mapping Analysis, MD Details, April 2020

Claims Data Analysis Supports US Market Opportunity: ~3,000 Galactosemia Patients

Distribution of US Galactosemia Population Based on Claims Data



~60% of Claims in Top 10 States

State	Projected Population	Projected Population %
FL	358	12%
CA	283	9%
TX	281	9%
IL	191	6%
NJ	146	5%
OH	129	4%
VA	129	4%
NY	122	4%
PA	122	4%
IN	107	3%

Key Claims Data Analysis Findings:

- Majority of claims coding for Galactosemia ≤ 18 yr
- Top 3 states (FL, CA, TX) have ~30% of all claims

Projected Claims by Age and Sex (All States)

Age Group	Female	Male	Grand Total
<2	313	264	577
2-6	456	543	999
7-12	210	204	414
13-18	155	138	294
19-34	219	192	410
35-54	112	82	194
55-64	43	38	81
65+	60	54	114
Grand Total	1568	1515	3083

Decision Resources Group, Galactosemia Claims Data Report, June 3, 2020.

Market Research Indicates High Patient and HCP Interest in New Treatment; Payers Anticipate Covering Similar to Other Rare Disease Products

HCP Market Research¹

- **100% responded 'yes' when asked if they would Rx for their patients**
- Most want to see long-term clinical outcomes, but are **willing to use upon biomarker approval if safe and well tolerated**

"It's hard - no matter how strict, how compliant, they are still going to get long term complications, even those we identify early on. It's frustrating. So variable. Even if you have siblings, even if you have the same mutation."

"I can save their lives, but I'm not saving their brains... that's disappointing."

Patient Market Research¹

- Families are **very excited** about the prospect of a treatment; **100% responded 'yes' when asked if they would ask for this Tx / give to their child**
- Willing to use if proven "safe," even if efficacy data is not long-term
- **Sense of urgency to use as early as possible**, to prevent issues before they begin
- Families with school-age children and those who are severely affected are **very attuned to developmental delays and concerned about CNS symptoms that develop later, like seizures**

U.S. Payer Market Research²

- Payers liked the **fast onset and sustained reduction in galactitol, no concerns with safety profile, reacted favorably to QD dosing and ability to penetrate CNS**
- Noted **similarity to other orphan drugs with only biomarker efficacy** at launch and later long-term outcomes; **will cover if approved with only biomarker-based endpoint**
- Payers expect AT-007 to be **managed similarly to other rare metabolic therapies**, covered on specialty tier, with PA to trial criteria and re-authorization based on patient biomarker response to therapy

1. Galactosemia HCP & Patient Journey Market Research, June 3, 2020 2. Trinity Partners Payer Insights Report, July 14 2020. Market Research included 5 US Payers. US screening criteria limited to Pharmacy Directors at larger national or regional plans that cover > 5M lives, familiar with rare metabolic disorders and currently vote on P&T Committee for rare metabolic disorders


Award-Winning Disease State Awareness Campaign Effectively Engaging with and Educating the Galactosemia Community Prior to Launch

HCP


MEDIA




SOCIAL



EMAIL




3D MOD VIDEO




HCP & PATIENT / CAREGIVER

WWW.GALACTOSEMIA.COM



YOUTUBE



SEARCH




PATIENT / CAREGIVER

MEDIA




SOCIAL



2D MOD VIDEO



EMAIL





AT-007 Commercial Opportunity

Significant unmet need with no approved treatment

Potential for pricing in-line with other rare diseases

Caregiver / patient and HCP enthusiasm and willingness to ask for / Rx at launch

Appealing product profile, including oral once-daily dosing and favorable safety profile

Relatively small commercial footprint to be focused on Centers of Excellence

Exclusivity through 2037 and possible regulatory extension of term

Potential to be the first disease-modifying therapy for Galactosemia

AT-007 SORD DEFICIENCY

Preclinical proof of concept demonstrated

Pilot study completed; Registrational study expected Q4 2021



SORD Deficiency is One of the Most Common Recessive Causes of Hereditary Neuropathy, Impacting ~3,000 US Patients

- **Sorbitol Dehydrogenase Deficiency** (SORD Deficiency) is a progressive, debilitating hereditary neuropathy that affects peripheral nerves and motor neurons, resulting in significant disability, loss of sensory function and decreased mobility


- Recently identified mutations in the SORD gene resulting in **loss of enzyme Sorbitol Dehydrogenase (SORD) function** and consequent **intracellular sorbitol accumulation**

- Previously, these patients were diagnosed as a subset of patients with Charcot-Marie-Tooth disease Type 2 (CMT2) or Distal Hereditary Motor Neuropathy (dHMN)


- **~3,300 individuals in the US with SORD Deficiency** (~7-9% CMT2/dHMN patients)

- SORD's **role in metabolism is well defined**, and an understanding of this genetic and biochemical basis of disease offers **new opportunities for treatment** of patients with neuropathy caused by SORD deficiency

Aldose Reductase Inhibition Addresses the Underlying Cause of SORD by Preventing Conversion of Glucose to Sorbitol





- Patients have very high levels of sorbitol in their cells and tissues as a result of SORD enzyme deficiency
- High toxic sorbitol levels results in cell death and tissue degeneration, such as neuropathy.
- AT-007 significantly reduced sorbitol levels in SORD patient fibroblasts




Applied Therapeutics, data on file; pilot study

AT-007 Substantially Reduced Sorbitol in Patients with SORD Deficiency in 30-Day Open-Label Pilot Trial

Pilot open-label study data in 8 SORD patients demonstrated mean reduction from baseline of 66% (range 54%-75%)



Inherited Neuropathy Consortium Centers of Excellence and Global CMT Registries Exist to Support Trial Enrollment & SORD Patient Treatment



Available from: <https://www.rarediseasesnetwork.org/cms/inc/centers#CSMC>. Last accessed August 25, 2020

AT-007: Potential First Therapy for SORD Deficiency

High Unmet Need in SORD

- No approved therapies; limited pipeline for generalized CMT2
- Causes substantial decrease in patient QoL
- Diagnosed in early stage, where treatment may prevent disability progression and positively impact prognosis and QoL

AT-007 Opportunity

- Validated mechanism of action, penetrates CNS
- Favorable safety & tolerability profile
- Convenient oral dosing to optimize adherence and minimize patient burden
- Sorbitol reduction biomarker based clinical development for Accelerated Approval
- Registrational study start expected Q4 2021

AT-007 is expected to be the first disease-modifying therapy for SORD, targeting the underlying cause of disease

AT-007

PMM2-CDG

- Orphan Drug Designation
- Pediatric Rare Disease Designation (PRV)

Preclinical proof of concept

Phase 2 ready- clinical study start 2021

Expanded Access program open



What is PMM2-CDG?

Glycosylation is a process by which sugars are chemically attached to proteins to form glycoproteins, which are required by crucial functions within the human body

PMM2-CDG[†], is an ultra-rare mutation of the PMM2 gene (phosphomannomutase) which **results in loss of PMM2 protein function and systemic deficient glycosylation of proteins, disrupting the function of critical tissues and organs**


Level of PMM2-CDG activity correlates with severity of disease

PMM2-CDG is the most common congenital disorder of glycosylation


Diagnosed within the **first year of life** by pediatrician or pediatric neurologist based on clinical presentation; confirmed by medical geneticist at center of excellence

[†]PMM2-CDG = Phosphomannomutase-2 Deficiency, a Clinical Disorder of Glycosylation disease

Aldose Reductase Inhibition Improves PMM2 Activity, Addressing the Underlying Cause of PMM2-CDG



- AR inhibition blocks the polyol pathway, restoring glucose flow through normal metabolic pathways
- Promotes proper balance of precursor sugars necessary for protein glycosylation
- Results in increased PMM2 activity and protein glycosylation



AT-007: Potential First Therapy for PMM2-CDG

High Unmet Need in PMM2-CDG

- No approved therapies
- ~1,000 cases worldwide, with ~20% infant mortality
- Significant impact on QoL and patient morbidity/mortality
- Disease management is complex: symptoms are managed through supportive multidisciplinary care – nothing to prevent underlying pathogenesis of disease

AT-007 Opportunity

- Validated MOA, penetrates CNS
- Favorable safety & tolerability profile
- Convenient oral dosing to optimize adherence and minimize patient burden
- Low burden of development due to biomarker-based program under new FDA guidance for low prevalence diseases[†]
- Relatively small commercial footprint to be focused on COEs

*Clinicians and regulators are working together to develop a robust study
Urgent cases considered under expanded access program*

**AT-007 is expected to be the first disease-modifying therapy for PMM2-CDG,
directly targeting the underlying cause of disease**

[†]Diseases with less than 5,000 US patients are termed "low prevalence"

AT-001

DIABETIC CARDIOMYOPATHY

Ph 3 initiated in Q3 2019

Data read-out expected 1H '23



What is Diabetic Cardiomyopathy (DbCM)?

DbCM is a **form of heart failure (Stage B)**, diagnosed by echocardiogram, in which structural cardiac damage has occurred, resulting in decreased cardiac functional capacity

Hyperactivation of **the polyol pathway is a key underlying mechanism in DbCM and other diabetic complications**. In hyperglycemic and ischemic conditions, this pathway — **via Aldose Reductase (AR)** — causes intracellular sorbitol accumulation, osmotic stress, cell death, and generation of ROS


There are no approved therapies for DbCM, which affects ~17% of people with diabetes

~25% of patients with DbCM progress to overt heart failure or death within 1.5 years of diagnosis

Previous AR inhibitors studied in diabetic complications (including DbCM) **demonstrated clinical efficacy**, but were **associated with off-target safety signals** due to lack of selectivity and specificity

In Phase 1/2 trials, **AT-001 significantly reduced levels of sorbitol, a key toxic biomarker of Aldose Reductase function**, to the same levels as healthy volunteers

DbCM: Mechanism of Disease



Both Type 1 and Type 2 diabetes results in hyperglycemia; the **polyol pathway** is then hyperactivated to rid the body of the excess glucose


Aldose Reductase (the first and rate limiting enzyme in the polyol pathway) converts this glucose into **sorbitol** and eventually **fructose**

Excess **sorbitol** and **fructose** cause several downstream processes that result in **cell death, including osmotic dysregulation and ROS formation**

AR activation also detracts glucose from the energy efficient hexokinase/glycolytic pathway, **resulting in less energy production for cardiomyocytes**

This results in heart fibrosis, a “hardening” of the heart muscle, which means it cannot effectively pump blood to the rest of the body

Diabetic Cardiomyopathy is a Form of Stage B Heart Failure



No Current Treatments for DbCM

Patients present clinically with shortness of breath on exertion due to decreased cardiac functional capacity

Structural heart disease confirmed/ DbCM diagnosed by echocardiogram

No treatments exist; patients counseled on lifestyle modification to improve compounding risk factors

DbCM occurs in both Type 1 and Type 2 diabetics, despite glucose control

AT-001 Phase 1/2 Trial in Type 2 Diabetes Demonstrated Safety, Clinical Proof-of-Concept via Normalization of Sorbitol & Effect on NTproBNP

Dose Range Finding

80 T2D Participants[†] | 7 Days

Endpoints / Results

Safe and well tolerated

Normalization of sorbitol (PD biomarker)

Single Ascending Dose (n=40)

5mg/kg

10mg/kg

20mg/kg

40mg/kg

Placebo

Multiple Ascending Dose (n=40, 7 days)

QD: 5mg/kg – 20mg/kg – 40mg/kg

BID: 20mg/kg

Placebo

Biomarker-Based Outcome

26 DbCM Participants | 28 Days

Endpoints/ Results

Safety: No drug-related AEs or abnormal labs[†]

Effect on cardiac biomarker NTproBNP

1,500mg BID Dosing (n=10)


1,000mg TID Dosing (n=10)

Placebo (n=6)

[†]All participants remained on concomitant medications

AT-001 Normalizes Sorbitol, a Biomarker of AR Activity, in Diabetic Patients


Proof of Biological Activity



— Sorbitol (whole blood) Healthy volunteer sorbitol avg.
 — AT-001 levels Diabetic patient sorbitol avg.

AT-001 normalized sorbitol in diabetics to healthy volunteer levels

Sorbitol Reduction by Dose




— Day 1 — Day 7

Mean reduction in sorbitol at Day 1 and Day 7: Results are persistent over 1 week of treatment

At 40mg/kg patients were normalized to healthy volunteer sorbitol levels, demonstrating complete AR inhibition

Sorbitol Normalization Over Time




— Placebo — 5mg/kg
 — 20mg/kg — 40mg/kg

Rapid release capsule provides sorbitol normalization effects (PD biomarker) through **10-12hrs post-dose** at >10mg/kg

Includes protection from food-related sorbitol spikes during times of post-prandial hyperglycemia

AT-001 Reduced Levels of NTproBNP Cardiac Stress Biomarker Over 28 Days


Sorbitol Normalization



Significant sorbitol reduction achieved by both 1,000mg TID and 1,500mg BID AT-001

Higher Cmax achieved with BID slightly beneficial — normalizes sorbitol to healthy volunteer levels


Mean Reduction in NTproBNP



Mean reduction in NTproBNP seen over 28 days vs. placebo

Mean baseline NTproBNP was 65pg/ml

Clinical Responder Analysis




~50% AT-001 treated patients demonstrated a clinically meaningful reduction in NTproBNP over 28 days

>25pg/ml reduction from baseline

DbCM Phase 3 Registrational Study (ARISE-HF)

Randomized, Placebo-Controlled Study in DbCM Patients at High Risk of Progression



ARISE-HF: Study Objectives

Primary Efficacy Objective

To demonstrate that AT-001 improves or prevents the decline of cardiac functional capacity in patients with Diabetic Cardiomyopathy (DbCM) at high risk of progression to overt heart failure

Secondary Efficacy Objective

To demonstrate that AT-001 decreases the progression to overt heart failure (Stage C HF)

The background features a faded image of a smiling couple, a man and a woman, looking towards the left. Overlaid on this are faint chemical structures, including a benzene ring, a carboxylic acid group (COOH), and a sulfonamide group (SO₂NH₂).

AT-001 Has Potential to be First Product to Treat DbCM, a Form of Heart Failure Affecting 17% of Diabetics

Appealing product profile, with convenient oral dosing; safe and well-tolerated

Significant unmet need with no approved treatment


Potential for pricing in-line with SGLT2s and Entresto

Diagnosis confirmed by echocardiogram

Exclusivity through 2031 and possible regulatory extension of term

Potential to be first product approved to treat DbCM

Significant Progress Over Five Years Supports Strategy and Execution



Intellectual Property Summary

Composition of matter patents and freedom to operate on key compounds

Expected IP runway of at least 10 years post-launch in key indications

In-licensed composition of matter patents that cover AT-007 and related compounds (US)

- Patent protection through 2037, regulatory extension of term possible
- European patent application has been allowed (patent has not yet issued); patent applications are pending in other countries

In-licensed composition of matter patents that cover AT-001 and related compounds (US, EP, JP, CA and AU)

- Patent protection through 2031, regulatory extension of term possible
- Method claims obtained or currently being pursued

Company-owned patent applications that cover methods for treating Galactosemia are pending in 13 countries, and a company-owned international application (PCT) that covers additional compound derivatives is pending

Company-owned provisional patent applications that cover methods for treating PMM2 deficiency and other indications are pending